CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

Market Cap	2.65M 2.28M 2.15M 1.96M 3.66M 253M 3.69M 25.59M 9.85M 128M 9.94M 9.72M 408M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.5M 21.07M 19.88M 18.11M 33.86M 2.34B 34.17M 237M 91.13M 1.19B 92.01M 90M 3.77B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

EntreMed Inc Stock Nasdaq

Stocks

US29382F2020

Pharmaceuticals

Valuation : EntreMed Inc

Latest news : EntreMed Inc

Press Releases : EntreMed Inc

Managers and Directors : EntreMed Inc

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.30%	-2.89%	+49.23%	+89.09%	1,002B
JOHNSON & JOHNSON	-0.22%	-4.37%	+51.47%	+63.70%	644B
ABBVIE INC.	+0.62%	-3.15%	+19.08%	+69.10%	443B
ROCHE HOLDING AG	-0.63%	-3.09%	+29.84%	+36.08%	343B
NOVARTIS AG	+0.43%	-14.61%	+11.32%	+26.98%	262B
ASTRAZENECA PLC	+0.93%	-3.19%	-1.31%	+11.96%	245B
AMGEN INC.	-2.36%	-14.07%	+37.03%	+45.82%	212B
NOVO NORDISK A/S	-0.90%	-5.06%	-18.47%	-58.14%	199B
GILEAD SCIENCES, INC.	-0.51%	-4.35%	+25.50%	+87.75%	181B
Average	-0.11%	-5.00%	+22.63%	+41.37%	392.19B
Weighted average by Cap.	+0.03%	-4.24%	+31.89%	+55.89%

	2024	2025
Net sales	28.54M 24.54M 23.16M 21.09M 39.43M 2.73B 39.79M 276M 106M 1.38B 107M 105M 4.4B	20.71M 17.81M 16.81M 15.31M 28.62M 1.98B 28.88M 200M 77.03M 1B 77.78M 76.08M 3.19B
Net income	-39.26M -33.76M -31.86M -29.02M -54.25M -3.75B -54.74M -379M -146M -1.9B -147M -144M -6.05B	-48.06M -41.33M -39M -35.52M -66.41M -4.59B -67.01M -464M -179M -2.33B -180M -177M -7.4B
Net Debt	6.05M 5.2M 4.91M 4.47M 8.36M 578M 8.44M 58.47M 22.5M 293M 22.72M 22.22M 932M	21.85M 18.79M 17.73M 16.15M 30.2M 2.09B 30.47M 211M 81.28M 1.06B 82.07M 80.27M 3.37B

End-of-day quote Nasdaq
- ^USD	-